Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Daily News

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

L.A. McKeown

June 18, 2024

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

PAD Significantly Ups Morbidity and Mortality in AMICS

L.A. McKeown

March 29, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Daily News

Recovered Paclitaxel PAD Data Shift the Mortality Picture

L.A. McKeown

May 14, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

Burden of Readmission High in PAD Patients Following Revascularization

L.A. McKeown

December 04, 2017

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

Top Endovascular News of 2023

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

High Lp(a) May Predict Risk of CV and Limb Events in PAD

PAD Significantly Ups Morbidity and Mortality in AMICS

Routine IVUS in Peripheral Interventions Supported by Small RCT

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Recovered Paclitaxel PAD Data Shift the Mortality Picture

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Burden of Readmission High in PAD Patients Following Revascularization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content